Hatch-Waxman is supposed to be about--at least paragraph 4 certifications--challenging invalid or not infringed patents.
In fact, after the Supreme Court ruling, an industry analyst said in a CNBC interview that the court created a 'holy mes...
that these particular type of settlements are delaying entry into the market and hurting consumers and the U.S. Governme...
To me, when you look at the numbers and the change since those Circuit Court decisions, this is more than just about som...
I think they assume that because for a number of years they were settled without pay for delay.
We urge Congress to take action on Senate bill 214, the Preserve Access to Affordable Generics Act.
I think that there would be benefits of billions of dollars from outlawing these reverse payment settlements.
Pay-for-delay settlements are the most egregious form of antitrust violation in my mind.
The CBO, as we know, expects this legislation would accelerate the availability of generic drugs and save $4.7 billion o...
You have an FTC which probably does not have the resources to match yours and the pharmaceutical industry.
Many more cases settle without pay-for-delay than with pay-for-delay.
What incentive do they have not to do it?
It seems to me the evidence suggests that just putting it back to rule of reason should have--should do the trick based ...
It is the pay-for-delay settlement that we have concerns about, Senator Grassley and I, Senator Vitter and Senator Frank...
What our bill would do is fairly simple. It provides subsequent filers with an exclusivity period if the first filer rel...
I'm proud to sponsor the Klobuchar-Grassley Preserve Access to Affordable Generics Act.
When I was at the State fair in 2009 during the heated debate about the ACA, a woman in her 60s came up to me and she sa...
One of the most common concerns I hear from seniors is that prescription drugs cost too much.
